Article Text
Abstract
Making the diagnosis of a particular type of limb girdle muscular dystrophy (LGMD) can appear challenging. In fact, various clues from the way the patient presents, and the results of simple investigations such as creatine kinase levels, can be extremely helpful in sorting out the various disease entities within this group of patients. The results of more specialised testing of the muscle biopsy and DNA sequencing offer the prospect of a clear answer in around 75% of cases. As more is understood about the clinical features of the different types of LGMD, targeted management is increasingly possible, especially focusing on those patients at high risk of cardiac and respiratory complications.
Statistics from Altmetric.com
Footnotes
Competing interests None.
Funding The Newcastle Muscle Centre is funded by the Muscular Dystrophy Campaign, the Medical Research Council and the European Union (TREAT-NMD contract number EC 036825).
Detail has been removed from these case illustrations to ensure anonymity. The editor and reviewer have seen the detailed information available and are satisfied that the information backs up the case the author is making.
Provenance and peer review: Commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Diagnosis and new treatments in muscular dystrophies
- Making sense of the clinical spectrum of limb girdle muscular dystrophies
- Muscle disease
- Screening of calpain-3 autolytic activity in LGMD muscle: a functional map of CAPN3 gene mutations
- Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity
- Respiratory involvement in inherited primary muscle conditions
- The muscular dystrophies
- FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients
- The effect of calpain 3 deficiency on the pattern of muscle degeneration in the earliest stages of LGMD2A
- Muscle hypertrophy and pseudohypertrophy